top of page
RESEARCH ARTICLE

      Abstract    

        

HOME

ANTIBIOGRAM OF BACTERIAL ISOLATES FROM BLOODSTREAM INFECTIONS IN CRITICAL CARE UNITS AT SHARDA HOSPITAL

 

A Srivastava, G Chauhan, SP Singh

 

ABSTRACT: Background: Bloodstream infections (BSIs) are a major cause of morbidity and mortality in critically ill patients, often complicated by multidrug-resistant organisms. Timely identification of causative pathogens and their antibiotic susceptibility patterns is essential for guiding effective therapy.

Objective: To determine the prevalence of bacterial isolates from BSIs and assess their antibiotic susceptibility patterns in patients admitted to the critical care units of Sharda Hospital. Methods: A prospective observational study was conducted over a defined period in the ICU and other critical care areas of Sharda Hospital. Blood samples from suspected BSI cases were cultured and processed using standard microbiological techniques. Isolates were identified, and antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method in accordance with CLSI guidelines. Results: A total of 66 positive blood cultures were analysed. Gram-negative bacteria were predominant, with Klebsiella pneumoniae and Escherichia coli as the most common isolates, while among Gram-positive organisms, Staphylococcus aureus (including MRSA) was frequently isolated. Alarmingly high resistance rates were observed against cephalosporins and fluoroquinolones among Gram-negative isolates. Carbapenems showed better efficacy but with emerging resistance. Vancomycin and linezolid retained high sensitivity among Gram-positive isolates. Conclusion: The study highlights a significant burden of multidrug-resistant pathogens causing BSIs in critical care settings. Regular surveillance of antibiograms and adherence to antibiotic stewardship policies are imperative to optimize treatment outcomes and curb antimicrobial resistance.

 

Keywords: Bloodstream infections, antibiogram, critical care, multidrug resistance, Sharda Hospital, ICU, antimicrobial susceptibility

​

​

REFERENCES:​​

  1. [1].  Gandra S, Mojica N, Klein EY, Ashok A, Nerurkar V, Kumari M, et al. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures in India: a multicentre study (2008–2014). Int J Infect Dis. 2016; 50:75–82.

  2. [2].  Joshi S, Soman R, Mahadik K, Kagal A, Ghosh A, Koppikar G, et al. antimicrobial resistance trends in bloodstream pathogens from Indian ICUs: data from the INICC database (2010–2017). Indian J Crit Care Med. 2020;24(2):117–24.

  3. [3].  Roy I, Jain A, Kumar M, Agarwal SK. Bloodstream infections and antimicrobial susceptibility patterns in a North Indian tertiary care hospital. J Lab Physicians. 2019;11(1):50–5.

  4. [4].  Singh AK, Venkatesh V, Singh R, Singh M. Epidemiology and antimicrobial susceptibility of bacterial pathogens causing bloodstream infections in a tertiary care hospital in North India. Indian J Med Res. 2018;147(6):563–70.

  5. [5].  Wattal C, Oberoi JK, Goel N, Raveendran R, Khanna S, Rao BK. Antimicrobial resistance in ICU pathogens in a tertiary care hospital in Delhi, India. J Assoc Physicians India. 2014;62(5):20–5.

  6. [6].  Mehta Y, Gupta A, Todi S, Myatra SN, Samaddar DP, Patil V, et al. Multidrug-resistant Gram-negative bacteria: how to treat and for how long? Crit Care Med. 2015;43(12):2673–5.

  7. [7].  Sharma R, Yadav K, Pant S, Kaur R, Bhatia R. Antibiogram of bacterial isolates causing bloodstream infections in intensive care units in a tertiary care hospital. Indian J Pathol Microbiol. 2022;65(1):85–91.

  8. [8].  Rajeshwari K, Ramesh K, Manjunath GN, Ramya N. Prevalence and antimicrobial susceptibility pattern of Gram-positive isolates from blood cultures in intensive care units. J Clin Diagn Res. 2017;11(5): DC01–4.

  9. [9].  Nazir A, Sana I, Peerzada BY, Farooq T. Study of prevalence and antimicrobial susceptibility pattern of blood culture isolates from a tertiary care hospital of North India. Int J Res Med Sci. 2018;6(12):4046–52.

  10. [10]. Berit EC, Maria PS, Jörg G, Salima M, Martin K, Oleg K. Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray. J Clin Microbiol. 2006;44(7):2389–97.

  11. [11]. Alvarez-Fernández C, et al. Clinical outcomes of colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections in India: retrospective multicentre analysis. Infect Control Hosp Epidemiol. 2017;38(5):559–64.

  12. [12].  Rajendran P, et al. Tigecycline and colistin susceptibility patterns in carbapenemase-producing Gram-negative bacteria in Tamil Nadu. J Med Microbiol Diagn. 2020;9(3):100038.

  13. [13]. Smith J, et al. Nine-year trends in tigecycline resistance among Acinetobacter baumannii BSI isolates. Eur J Clin Microbiol Infect Dis. 2024;43(2):101–9.

  14. [14]. Qureshi S, et al. Colistin, polymyxin B, and tigecycline susceptibilities in MBL-producing A. baumannii. Asian Pac J Trop Biomed. 2018;8(2):104–10.

  15. [15].  Patel R, et al. Carbapenem-resistant E. coli and Klebsiella in pediatric BSIs: colistin and tigecycline susceptibility in rural India. Indian Pediatr. 2017;54(12):1021–4.

  16. [16]. Syed B, et al. Emergence of colistin-resistant Gram-negative rods in ICUs: cross-sectional study from Pakistan. SAGE Open Med. 2022; 10:20503121221132358.

  17. [17]. Kumar S, et al. Carbapenem- and colistin-resistant Enterobacteriaceae: lab surveillance in India (2021–23). Indian J Med Microbiol. 2023;41(1):40–4.

  18. [18]. Ahmed A, et al. regional patterns of colistin and tigecycline resistance: South Asia surveillance. BMC Infect Dis. 2025; 25:345.

  19. [19]. Lee H, et al. Global trends in tigecycline and colistin susceptibilities (2016–21): ATLAS data. Int J Antimicrob Agents. 2023;62(3):106930.

  20. [20]. Verma M, et al. Colistin susceptibility among MDR Gram-negative blood isolates in Delhi tertiary care center (Jan 2023–Jun 2024). Biores Sci. 2025;2(1):15–21.

  21. [21]. Zhang X, et al. DNA microarray genotyping and virulence/resistance profiling of MRSA bloodstream isolates. J Clin Microbiol. 2012;50(10):3451–7.

  22. [22]. Sharma P, et al. Five-year surveillance of BSI pathogens and AMR trends in central India oncology patients. PLoS One. 2022;17(5): e0267890.

  23. [23]. Chopra S, et al. Mechanisms and epidemiology of tigecycline resistance in Enterobacteriaceae. Int J Antimicrob Agents. 2016;48(5):476–84.

  24. [24]. Singh R, et al. Colistin: spectrum of activity, resistance mechanisms, and global emergence. Clin Microbiol Rev. 2024;37(1): e00123-23.

  25. [25]. Yadav L, et al. Rise and transmission of NDM-1 carrying Enterobacterales in India—first report. Lancet Infect Dis. 2010;10(10):1018–24.

  26. [26].Bush K, et al. Treatment options for CRE: colistin, aminoglycosides, and emerging β-lactamase inhibitors. Nat Rev Microbiol. 2023;21(4):205–19.

 To cite this article:

Srivastava A, Chauhan G, Singh SP. Antibiogram of bacterial isolates from bloodstream infections in critical care units at sharda hospital. Int J Med Lab Res. 2025; 10(2):54-59. http://doi.org/10.35503/IJMLR.2025.10208

bottom of page